June 10, 2021 – Medtronic plc (Dublin, Ireland) has received U.S. Food and Drug Administration (FDA) approval for Vanta, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years.
The Vanta neurostimulator utilizes Medtronic’s proprietary AdaptiveStim technology for personalized pain relief that adapts to the patient’s movement or body position using a built-in accelerometer. AdaptiveStim technology goes beyond in-office programming by automatically adjusting stimulation to maintain each patient’s optimal dose.
The Vanta neurostimulator also provides unmatched full-body MRI access with Medtronic SureScan technology.
Approximately 82% of SCS-implanted patients will need at least one MRI within five years of implant, the company says.
The Vanta neurostimulator represents a 10% increase in longevity compared to PrimeAdvanced, Medtronic’s previous generation recharge-free device. It is also 20% smaller than the PrimeAdvanced neurostimulator, with a more rounded, ergonomic contouring to offer enhanced comfort.
The Vanta system provides access to Snapshot reporting, Medtronic’s proprietary data insights solution, offering clinicians objective reporting of patient activity levels to empower objective health conversations. Clinicians and their patients wishing to trial the Vanta neurostimulator may also take advantage of CareGuidePro, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy journey. CareGuidePro is currently in limited commercial release with a full launch expected later this summer.
DTM SCS is currently available on the rechargeable Intellis SCS platform, and the company expects to share more information about its availability across the entire Medtronic spinal cord stimulator portfolio later this summer.